☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
Affimed
Affimed’s AFM13 + AlloNK Receives the US FDA’s Fast Track Designation for Relapsed or Refractory Hodgkin Lymphoma
September 13, 2023
Affimed Reports First Patient Dosing of AFM28 in the P-I Study for the Treatment of CD123-Positive Acute Myeloid Leukemia
March 29, 2023
PharmaShots Interview: Affimed's Andreas Harstrick Shares Insight on AFM13 and its Data Presented at ASH 2020
February 10, 2021
Load more...
Back to Home
Modal title
×
Modal body text goes here.
